ArticleNature communications2023
Tackling antibiotic resistance by inducing transient and robust collateral sensitivity.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Collateral sensitivity-harnessing microbial vulnerabilities as a solution to antimicrobial resistance.Molecular biology reports · 2026Review
- Prediction of Antimicrobial Resistance in People Living With Cystic Fibrosis Using Machine Learning.MedComm · 2026Article
- Robust antibiotic sensitization of pathogenic Pseudomonas aeruginosa via negative hysteresis in the cell envelope.Nature communications · 2026Article
- Evolutionary drivers of divergent collateral sensitivity responses during antibiotic therapy.Nature ecology & evolution · 2026Review
- Collateral effects of antibiotic resistance in Campylobacter jejuni.FEMS microbiology letters · 2026Article
- Cross-talk between Pseudomonas aeruginosa and urinary tract infections.World journal of urology · 2025Review
- Ciprofloxacin resistance rapidly declines in nfxB defective clinical strains of Pseudomonas aeruginosa.Nature communications · 2025Article
- Tripartite Loops Reverse Antibiotic Resistance.Molecular biology and evolution · 2025Article
- Ceftazidime-avibactam use selects multidrug-resistance and prevents designing collateral sensitivity-based therapies against Pseudomonas aeruginosa.Nature communications · 2025Article
- Effects of different mechanisms on antimicrobial resistance inMicrobiology spectrum · 2025Article
- Leveraging collateral sensitivity to counteract the evolution of bacteriophage resistance in bacteria.mLife · 2025Article
- Targeting efflux pumps prevents the multi-step evolution of high-level resistance to fluoroquinolone inMicrobiology spectrum · 2025Article
- Systematic mapping of antibiotic cross-resistance and collateral sensitivity with chemical genetics.Nature microbiology · 2025Article
- Epidemiological Trends and Drug Resistance Patterns of Carbapenem-Resistant Gram-Negative Bacteria: A Retrospective Study in a Tertiary Hospital in China (2019-2024).Infection and drug resistance · 2025Article
- Tobramycin-resistant small colony variant mutant ofVirulence · 2024Article
- Multidrug resistance in Pseudomonas aeruginosa: genetic control mechanisms and therapeutic advances.Molecular biomedicine · 2024Review
- Collateral sensitivity counteracts the evolution of antifungal drug resistance in Candida auris.Nature microbiology · 2024Article
- Drug combinations targeting antibiotic resistance.npj antimicrobials and resistance · 2024Review
- Preserving the efficacy of antibiotics to tackle antibiotic resistance.Microbial biotechnology · 2024Review
- β-lactamase expression induces collateral sensitivity in Escherichia coli.Nature communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Collateral sensitivity (CS) is an evolutionary trade-off traditionally linked to the mutational acquisition of antibiotic resistance (AR). However, AR can be temporally induced, and the possibility that this causes transient, non-inherited CS, has not been addressed. Mutational acquisition of ciprofloxacin resistance leads to robust CS to tobramycin in pre-existing antibiotic-resistant mutants of Pseudomonas aeruginosa. Further, the strength of this phenotype is higher when nfxB mutants, over-producing the efflux pump MexCD-OprJ, are selected. Here, we induce transient nfxB-mediated ciprofloxacin resistance by using the antiseptic dequalinium chloride. Notably, non-inherited induction of AR renders transient tobramycin CS in the analyzed antibiotic-resistant mutants and clinical isolates, including tobramycin-resistant isolates. Further, by combining tobramycin with dequalinium chloride we drive these strains to extinction. Our results support that transient CS could allow the design of new evolutionary strategies to tackle antibiotic-resistant infections, avoiding the acquisition of AR mutations on which inherited CS depends.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.